The Center for Research in Inflammatory Diseases (CRID) was created with the aim of producing integrative and translational scientific research to identify and validate new biological pathways involved in the induction and resolution of inflammation. To this end, it counts on the experience of researchers from various fields of Biomedical Sciences linked to basic research (genetics, molecular and cell biology, immunology, pharmacology, and pathology) and clinical research (rheumatology, immunology, infectology, and dermatology), in addition to researchers in the area of bioinformatics.
Inflammatory diseases constitute a complex and heterogeneous group of diseases that affect more than 10% of the world population. The treatment alternatives currently available are limited and, in some cases, ineffective, considering that information on the underlying mechanisms of the inflammatory process and the pathophysiology of inflammatory diseases is still lacking.
The specific objective of the Center is to advance knowledge about inflammatory diseases (infectious, autoimmune, and related to the cardiovascular system) to recognize and understand the molecular, immunological, pathological, and pharmacological mechanisms involved; identify new biological targets for the development of pharmacological therapeutic tools; search for possible diagnostic markers and prognostic indications, and apply new knowledge to design and synthesize molecules aimed at treating inflammatory diseases.
Brazilian researchers have developed a tool that encodes patient identification data as DNA sequences and integrates databases with millions of records despite misspellings and omissions. The platform is fast and accurate and can be used for epidemiological analysis and public policy formulation.
Research by groups at the University of São Paulo and the State University of Campinas combined MRI scans of the brains of mild COVID-19 patients, analysis of brain tissue from people who died of the disease and experiments on human nerve cells infected in the laboratory.
While some patients die with a high viral load and little inflammation, others succumb to inflammatory complications that arise after the virus is eliminated from the organism. According to scientists at the University of São Paulo, lasting inflammasome activation is key in such cases. The findings can be used to develop personalized therapeutic approaches.
Brazilian researchers have developed an algorithm to identify the protozoan Trypanosoma cruzi in photographs of blood samples taken with a mobile phone camera. The low-cost method is described in the journal PeerJ and can be reproduced.
The discovery is reported by researchers at Harvard University and the University of São Paulo in Nature Neuroscience, and could serve as a basis for the development of treatments for different diseases.
In a study conducted by researchers at the University of São Paulo involving experiments on mice, the synthetic substance not only prevented the neuropathic pain typically induced by chemo drugs but was also beneficial against cancer.
Researchers affiliated with a FAPESP-funded research center showed that a protein called gasdermin D is involved in septic patients’ organ lesions. The study also proved that a drug originally indicated to treat alcohol dependence can inhibit the molecule’s action and prevent complications.
Many patients suffer from a significant decline in immunity lasting for years after they are discharged from hospital. In an article published in the journal Immunity, Brazilian researchers reveal why this happens.
A group at the University of Campinas used protein mapping to show how abnormal levels of the neurotransmitter glutamate impair the functioning of neurons and oligodendrocytes. The findings could serve as a basis for more effective treatment.